Kaplan Fox notifies investors of securities class action against Corcept Therapeutics, Inc. (CORT)

Kaplan Fox & Kilsheimer LLP recently reported a class action lawsuit lodged against Corcept Therapeutics, Inc. on behalf of individuals or entities who acquired Corcept common stock from October 31, 2024, to December 30, 2025. The complaint alleges that Corcept, a pharmaceutical company specializing in medications to address various disorders by modulating cortisol effects, falsely represented the status of their product relacorilant. This new product candidate was purported to be nearing approval for treating hypercortisolism; however, the FDA had voiced concerns about the supporting clinical evidence. On December 31, 2025, Corcept disclosed that the FDA had issued a Complete Response Letter stating a lack of substantial evidence to support relacorilant’s effectiveness, resulting in a significant stock price decline.

Kaplan Fox, a distinguished law firm with over five decades of experience in securities litigation, stands ready to assist those impacted by potential market losses associated with Corcept Therapeutics, Inc. Their expertise spans complex litigation across different states and hierarchical levels, enabling them to secure favorable outcomes for their clientele. This agency has been instrumental in shaping the law by prevailing in crucial cases, such as securities fraud lawsuits. Despite being considered Attorney Advertising in certain jurisdictions, Kaplan Fox’s historical successes speak volumes about their proficiency in handling legal matters pertaining to securities law.

Concerned investors are advised to reach out to Kaplan Fox for further assistance by April 21, 2026, if they wish to participate in the lawsuit as a lead plaintiff. While taking on such a role is optional, engaging with legal experts like Kaplan Fox can potentially lead to a more favorable resolution and financial recovery. Jeffrey P. Campisi and Laurence D. King, two prominent legal practitioners associated with Kaplan Fox & Kilsheimer LLP, are available for inquiries and necessary legal support regarding this case. It is essential to note that contacting or providing information to Kaplan Fox does not automatically establish an attorney-client relationship or obligate them to represent you.

In conclusion, the ongoing class action lawsuit against Corcept Therapeutics, Inc. underscores the importance of transparency and accountability in the pharmaceutical sector. Investors are urged to seek legal counsel in case of potential losses resulting from misleading representations by companies in the healthcare industry. Kaplan Fox’s robust track record in handling securities litigation instills confidence in their capability to navigate complex legal nuances and deliver favorable outcomes for affected parties. As the deadline for potential lead plaintiffs approaches, it is crucial for impacted investors to consider their legal options and explore avenues for possible recovery in light of the recent developments surrounding Corcept Therapeutics, Inc.